Candel Therapeutics Inc. (NASDAQ: CADL) announced the publication of results from its pivotal phase 3 clinical trial of aglatimagene besadenovec ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE